ORI Capital is a Hong Kong and US biotechnology venture investor founded in 2015. It backs early-stage therapeutics, drug-delivery technologies and diagnostics addressing serious diseases, including cancer, cardiovascular and metabolic disorders, and neurodegenerative diseases. The firm combines scientific due diligence with its proprietary ORIZON data and AI research platform to identify investment opportunities and support portfolio companies. Its strategy spans small-molecule drugs, DNA and RNA medicines, cell therapies and synthetic biology. ORI Capital Limited is the published manager identity; its funds and investment subsidiaries are distinct legal vehicles.
Founded
2015
Type
Venture capital
Funds1
ORI Healthcare Fund II, L.P.$260M
ORI Capital’s second healthcare venture fund invests globally in early-stage biotechnology, including novel therapeutics, diagnostics and drug delivery for serious diseases such as neurodegenerative disorders. It combines scientific investment research with the manager’s ORIZON AI and data platform.
